Industry-Supported Symposium
David Chang, MD, MPH (he/him/his)
Cabaletta Bio
Philadelphia, Pennsylvania, United States
Disclosure information not submitted.
Rohit Aggarwal, MD, MS
Professor
University of Pittsburgh
Pittsburgh, PA, United States
Disclosure information not submitted.
Dinesh Khanna, MD, MSc
University of Michigan
Ann Arbor, Michigan, United States
Disclosure information not submitted.
Please note: This session is not eligible for CME Credits through ACR.
This session will not be recorded for on-demand.
Join our faculty for an interactive session describing the state of the art of CAR T cell therapy in autoimmune disease. Following short presentations that summarize the latest cell therapy data in myositis, systemic sclerosis, and lupus as well as late stage clinical trial designs, our faculty will participate in an interactive panel discussion focusing on the future of CAR T cell therapy in autoimmune disease. This symposium will provide an overview of the RESET clinical trial program, evaluating the safety and efficacy of rese-cel, an investigational CD19-CAR T cell therapy. Other investigational CAR T cell therapies in autoimmune diseases will also be summarized. Developed and offered by Cabaletta Bio. Not an official program of the ACR.
